Supplementary Table S9. Clinical characteristics of b/tsDMARD-naïve RA subset initiating TNFi, selected by remission at 6 months.

Clinical parameters	b/tsDMARD-naïve RA patients starting TNFi who achieved remission (n=25)	6-months (n=25)
Male/Female (n/n)	5/20	-
Age, years (mean ± SD)	54.08 ± 9.50	-
Disease evolution, years (mean ± SD)	9.54 ± 7.95	-
TJC (mean ± SD)	6.12 ± 5.08	1.04 ± 1.51****
SJC (mean ± SD)	4.44 ± 4.81	0.40 ± 1.22***
DAS28-CRP (mean ± SD)	4.64 ± 1.09	2.55 ± 1.01****
SDAI (mean ± SD)	26.60 ± 11.24	9.72 ± 6.81****
CDAI (mean ± SD)	24.52 ± 10.98	8.96 ± 6.48****
HAQ (mean ± SD)	1.92 ± 0.45	-
Smoking (n, %)	7, 28.00%)	-
Hypertension (n, %)	7, 28.00%)	-
Laboratory parameters		
CRP, mg/mL (mean ± SD)	20.75 ± 26.19	7.55 ± 8.87**
ESR, mm/h (mean ± SD)	32.71 ± 31.73	18.48 ± 13.78
ACPAs positivity (n, %)	19, 76.00%	18, 72.00%
RF positivity (n, %)	23, 92.00%	20, 80.00%
Treatments		

Corticosteroids (n, %)	20, 80.00%	-
NSAIDs (n, %)	22, 88.00%	-
cDMARDs (n, %)	25, 100.00%	-

TJC (Tender Joint Count); SJC (Swollen Joint Count); DAS28-CRP (Disease Activity Score); SDAI (Simplified Disease Activity Index); CDAI (Clinical Disease Activity Index); HAQ (Health Assessment Questionnaire); CRP (C-reactive protein); ESR (Erythrocyte sedimentation rate); ACPA (Anti-citrullinated protein antibodies); RF (Rheumatoid Factor); NSAID (Non-steroidal anti-inflammatory drug); cDMARD (Conventional DMARDs). Statistical significance levels respect to baseline time were designated as follows: (****) <0.0001 p-value; (***) <0.001 p-value; (**) <0.01 p-value; (*) <0.05 p-value.